The levels of TAO kinase 1, which activates p38 MAPK cascades and is a potential therapeutic target for cancers with defective β-catenin signalling such as hepatocellular carcinoma [24], were significantly up-regulated. The gene discussed is TAOK1; the disease is cancer.